Drug Trial Radar · NCT04749368
Study to Investigate the Safety and Efficacy of BRII-835 and BRII-179 Combination Therapy Treating Chronic Hepatitis B Virus (HBV) Infection
Last checked: Nov 20, 2026Latest source record: Jul 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
91
Actual
Start
Apr 12, 2021
Primary completion
Jul 4, 2023
Study completion Jul 4, 2023
Sponsor
- Lead sponsor
- Brii Biosciences LimitedIndustry
- Sponsor type
- Industry
- Collaborators
- Vir Biotechnology, Inc.; VBI Vaccines Inc.
- First posted
- Feb 11, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open label, randomized, parallel-group study to evaluate the safety and efficacy of combination treatment BRII-835 (VIR-2218) and BRII-179 (VBI-2601) in adult participants with chronic HBV infection
Conditions
- Hepatitis B, Chronic
Interventions
BRII-835 (VIR-2218)Drug
BRII-835 (VIR-2218) will be given by subcutaneous injection
BRII-179 (VBI-2601) with IFN-αBiological
BRII-179 (VBI-2601) with IFN-α will be co-administered by intramuscular injection
BRII-179 (VBI-2601)Biological
BRII-179 (VBI-2601) will be administered by intramuscular injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Sustained HBsAg Loss During the 48-week Follow-up Period After NRTI WithdrawalTime frame: Up to Week 96
- Number of Participants With Adverse Events (AE)Time frame: Up to Week 96
- Number of Participants With Serious Adverse Events (SAE)Time frame: Up to Week 96
- Number of Participants With Abnormalities in Clinical Laboratory TestsTime frame: Up to Week 96
Locations
28 sites in 6 countries. Site status is shown where the registry gives one.
Investigative Site 61002
Kingswood, New South Wales, Australia
Investigative Site 61001
Westmead, New South Wales, Australia
Investigative Site 61004
Herston, Queensland, Australia
Investigative Site 88602
Changhua, Taiwan, China
Investigative Site 85201
Hong Kong, China
Investigative Site 85202
Hong Kong, China
Investigative Site 85203
Hong Kong, China
Investigative Site 88601
Kaohsiung, Taiwan, China
Investigative Site 88604
Kaohsiung, Taiwan, China
Investigative Site 85204
NEW Territories, Hong Kong, China
Investigative Site 88603
Taichung, Taiwan, China
Investigative Site 88605
Taipei CITY, China
Investigative Site 64001
Auckland, New Zealand
Investigative Site 64002
Dunedin Central, Dunedin, New Zealand
Investigative Site 65001
Singapore, Singapore
Investigative Site 65002
Singapore, Singapore
Investigative Site 82004
Busan, South Korea
Investigative Site 82003
Seongnam-si, Gyeonggi-do, South Korea
Investigative Site 82001
Seoul, South Korea
Investigative Site 82005
Seoul, South Korea
Investigative Site 82002
Seoul, South Korea
Investigative Site 66001
Bangkok, Thailand
Investigative Site 66003
Chiang Mai, Thailand
Investigative Site 66002
Khon Kaen, Thailand
Investigative Site 66005
Nonthaburi, Thailand
Investigative Site 66006
Nonthaburi, Thailand
Investigative Site 66004
Pathum Thani, Thailand
Investigative Site 66007
Songkhla, Thailand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.